Development of a cancer genome personalized medicine screening system using the 3D organoid method.

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07757
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Keio University
• Principal Investigator: Takaishi Hiromasa 慶應義塾大学, 医学部(信濃町), 教授 (80286468)
• Co-Investigator(Kenkyū-buntansha): 加藤 容崇 社会医療法人北斗北斗病院(腫瘍医学研究所), 特任研究員, 特任研究員 (00708878) ; 西原 広史 慶應義塾大学, 医学部(信濃町), 教授 (50322805)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: オルガノイド / 癌ゲノム / 薬剤スクリーニング

Outline of Final Research Achievements

Cancer therapies based on molecular targeted drugs and antibody drugs based on the results of genetic analysis are becoming mainstream. While these drugs are highly effective, they are also extremely expensive, so accurate prediction of treatment efficacy is necessary. The purpose of this study is to research and develop a drug screening method using a 3D cell culture system, which has been the focus of much attention in recent years, in order to accurately predict therapeutic efficacy.
Through this research, we succeeded in establishing 271 different organoid cell lines for 503 cases of 5 different cancer types, and achieved an establishment success rate of 89.5% in FY2021 by improving the culture method.

Free Research Field

消化器癌

Academic Significance and Societal Importance of the Research Achievements

本研究により得られた知見は、オルガノイド細胞株を用いた研究の根幹を成すものであり、複数癌種において9割近い樹立成功率は世界的に見ても非常に高い水準であり、オルガノイドを用いた癌研究の根幹となる技術である。今後、これらのオルガノイド細胞株を用いて薬剤効果予測および耐性化予測に向けて解析を進めていく予定です。
今後、効率的に個々人に有効な薬剤を選択し、また耐性化を防ぐことで、医療資源の効率的な使用が可能になり、現代日本における大きな社会課題である医療費の削減に向けて、重要な知見が得られた。